Business
Interim Results
Interim Results.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma plc\n \n \n \n \n \n \n \n Interim results for the six months to 30 June 2022\n \n \n \n \n \n \n \n Significant strategic and operational progress\n \n \n \n \n \n \n 6 September 2022 -\n \n \n Poolbeg Pharma\n \n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'),\n a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022.\n \n \n \n \n \n \n Financial & Operational Highlights\n \n \n \n \n \n \n \n •\n \n \n \n \n Well capitalised with a strong cash balance of £18.9m as at 30 June 2022\n \n \n \n \n \n \n •\n \n \n \n \n Significant progress made on developing POLB 001, a treatment for severe influenza\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n LPS human challenge trial commenced in July 2022 with initial results expected by year end 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n Supply Agreement signed and GMP manufacturing completed\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n Key US patent granted in May 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n Continuing to explore further disease indications beyond severe influenza\n \n \n \n \n \n \n •\n \n \n \n \n Two AI programmes commenced to analyse Poolbeg's unique human challenge trial data\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n Agreement signed with OneThree Biotech Inc. in February 2022 to identify new drug targets and treatments for Respiratory Syncytial Virus (RSV). The programme is progressing well with the model build and optimisation completed in June 2022, with results expected by the end of 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n In March 2022 an agreement was signed with CytoReason Ltd. to identify novel drug targets for influenza. Data analysis is ongoing, and results are expected in Q2 2023\n \n \n \n \n \n \n •\n \n \n \n \n Licensed first-in-class broad spectrum RNA-based immunotherapy (POLB 002) for respiratory virus infections from the University of Warwick in January 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n -\n \n \n \n \n Key European and US patents granted in April and May 2022 respectively\n \n \n \n \n \n \n •\n \n \n \n \n Diligence completed on POLB 003, an intramuscular va...